CLINICAL TRIALS PROFILE FOR LUMIZYME

All Clinical Trials for LUMIZYME

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00158600 ↗	A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease	Completed	Genzyme, a Sanofi Company	Phase 3	2005-09-01	Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The overall objective is to evaluate the safety, efficacy, and pharmacokinetics (PK) of alglucosidase alfa treatment in patients with late-onset Pompe disease as compared to placebo.
NCT01380743 ↗	Drug-drug Interaction Study	Completed	Amicus Therapeutics	Phase 2	2011-10-31	This study evaluates drug-drug interactions between AT2220 (duvoglustat) and recombinant human alpha-glucosidase (rhGAA, also known as alglucosidase alfa) in participants with Pompe Disease.
NCT01526785 ↗	A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease	Terminated	Genzyme, a Sanofi Company	Phase 4	2012-03-01	The objective of this study was to evaluate the efficacy and safety of treatment with 4000 litre (L) alglucosidase alfa (Lumizyme®) in Pompe participants.
NCT02782741 ↗	Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease	Active, not recruiting	Genzyme, a Sanofi Company	Phase 3	2016-11-02	Primary Objective: To determine the effect of avalglucosidase alfa treatment on respiratory muscle strength measured by percent (%) predicted forced vital capacity (FVC) in the upright position, as compared to alglucosidase alfa. Secondary Objective: To determine the safety and effect of avalglucosidase alfa treatment on functional endurance (6-minute walk test, inspiratory muscle strength (maximum inspiratory pressure), expiratory muscle strength (maximum expiratory pressure), lower extremity muscle strength (hand-held dynamometry), motor function (Quick Motor Function Test), and health-related quality of life (Short Form-12).

Clinical Trial Conditions for LUMIZYME

Condition Name

Condition Name for LUMIZYME
Intervention	Trials
Pompe Disease	3
Acid Maltase Deficiency Disease	1
Glycogen Storage Disease Type II (GSD-II)	1
Glycogen Storage Disease Type II-Pompe's Disease	1

Condition MeSH

Condition MeSH for LUMIZYME
Intervention	Trials
Glycogen Storage Disease Type II	5
Glycogen Storage Disease	3
Deficiency Diseases	1

Clinical Trial Locations for LUMIZYME

Trials by Country

Trials by Country for LUMIZYME
Location	Trials
United States	67
United Kingdom	4
France	3
Netherlands	2
Canada	2

Trials by US State

Trials by US State for LUMIZYME
Location	Trials
California	5
North Carolina	4
Virginia	3
Ohio	3
Georgia	3

Clinical Trial Progress for LUMIZYME

Clinical Trial Phase

Clinical Trial Phase for LUMIZYME
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2
Phase 2	1

Clinical Trial Status

Clinical Trial Status for LUMIZYME
Clinical Trial Phase	Trials
Completed	2
Terminated	2
Active, not recruiting	1

Clinical Trial Sponsors for LUMIZYME

Sponsor Name

Sponsor Name for LUMIZYME
Sponsor	Trials
Genzyme, a Sanofi Company	3
Amicus Therapeutics	1
Sanofi	1

Sponsor Type

Sponsor Type for LUMIZYME
Sponsor	Trials
Industry	6

Lumizyme: Clinical Trial Status, Market Analysis, and Future Projections

Last updated: February 20, 2026

What is the current status of Lumizyme’s clinical development?

Lumizyme (alglucosidase alfa) is approved by the U.S. Food and Drug Administration (FDA) since 2010 for treating Pompe disease, a rare genetic disorder caused by the deficiency of the enzyme acid alpha-glucosidase. It is a recombinant enzyme replacement therapy (ERT). The drug has completed multiple clinical trials confirming its safety and efficacy in infants, children, and adults with Pompe disease.

Clinical Trials Overview

• Initial Approval: Based on Phase I/II trials demonstrating reductions in glycogen accumulation and improvements in muscle function.
• Ongoing Studies:
  • Phase IV post-marketing studies focus on long-term safety and effectiveness.
  • Trials investigating dosage optimization, infusion strategies, and combination therapies.
  • No recent large-scale Phase III trials registered as ongoing, suggesting the development phase has shifted to post-marketing.

Regulatory Submissions and Approvals

• Approved in the US, EU, Japan, and other markets.
• No recent NDA (New Drug Application) filings or approvals documented.
• The focus has shifted toward lifecycle management and real-world evidence collection.

What is the current market size and competitive landscape?

Market Size

• Global enzyme replacement therapy market for Pompe disease was valued at approximately USD 250 million in 2022.
• Expected to grow at a compound annual growth rate (CAGR) of 7.5% over 2023-2030.
• Major markets include North America (55%), Europe (25%), and Asia-Pacific (15%).

Competitors

Drug Name	Manufacturer	Approval Year	Indication	Market Share (Estimated)
Lumizyme	Genzyme (Sanofi)	2010	Pompe disease (Infantile & Adult)	65%
Nexviazyme (avalglucosidase alfa)	Genzyme (Sanofi)	2021	Pompe disease, long-term use	25%
Myozyme	Sanofi Genzyme	2006	Pompe disease	Superseded Lumizyme in some markets

Market Dynamics

• The substitution from Myozyme to Lumizyme in various markets was driven by manufacturing process improvements.
• The recent approval of Nexviazyme in 2021 has begun to encroach on Lumizyme's market share.
• The high cost of therapy, approximately USD 300,000 per year per patient, limits broad access.

What are the projections for Lumizyme's market?

Forecast Assumptions

• Market growth driven by increased diagnosis rates, especially in Asia-Pacific.
• Usage expansion in late-onset Pompe disease.
• Lifelong treatment adherence remains high.

Projected Financials

Year	Estimated Global Revenue (USD million)	Growth Rate
2023	160	4%
2025	180	12.5%
2030	250	56% (cumulative)

Key Market Drivers

• Expanded newborn screening programs in several countries.
• Rising prevalence of Pompe disease, estimated at 1 in 40,000 live births.
• Growing acceptance of early intervention approaches.

Risks and Challenges

• Competition from Nexviazyme with potentially improved efficacy.
• Pricing pressures from healthcare systems.
• Limited patient population constraining sales growth.

What are the strategic considerations?

• Continued development in gene therapy could threaten enzyme replacement options.
• Lifecycle management strategies involve patent extensions or new formulations.
• Collaborations with diagnostic companies can facilitate early detection and treatment initiation.

Key Takeaways

• Lumizyme remains the primary enzyme replacement therapy for Pompe disease since 2010.
• The clinical development stage is mature; ongoing focus on post-marketing data.
• Market share diminished by new competitors such as Nexviazyme, introduced in 2021.
• Market expansion depends on diagnosis rates and treatment accessibility.
• Revenue projections suggest moderate growth with potential for accelerated gains in emerging markets.

FAQs

1. Will Lumizyme's clinical trials be renewed for new indications?
No current public records indicate new trials for indications beyond Pompe disease.

2. How does Lumizyme compare in price to competitors?
Pricing is comparable; approximately USD 300,000 annually per patient. Negotiations and healthcare policies influence actual reimbursement.

3. What are common adverse effects reported in clinical trials?
Infusion-associated reactions, hypersensitivity, and respiratory issues; long-term safety is well-established.

4. Is there potential for Lumizyme to be replaced by gene therapies?
Gene therapies for Pompe are in early development phases; their market impact may take years to materialize.

5. How does the patient population size influence Lumizyme’s sales?
Pompe disease is rare; estimated global patient population is approximately 10,000. Market saturation and diagnosis rates heavily influence revenue.

---

Sources:

1. FDA. (2010). Approval of Lumizyme (alglucosidase alfa).
2. MarketsandMarkets. (2023). Enzyme Replacement Therapy Market by Type, Indication, Region – Global Forecast to 2030.
3. ClinicalTrials.gov. (2023). Lumizyme Clinical Trials Database.
4. GlobalData. (2022). Pompe Disease Market Report.
5. Sanofi. (2021). Nexviazyme Launch Announcement.